Imunon (NASDAQ:IMNN) Receives Hold Rating from D. Boral Capital

D. Boral Capital reiterated their hold rating on shares of Imunon (NASDAQ:IMNN) in a report published on Monday morning,Benzinga reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Imunon in a research note on Wednesday, March 26th.

Imunon Trading Down 2.9%

Shares of Imunon stock opened at $0.47 on Monday. The firm has a market cap of $6.87 million, a P/E ratio of -0.25 and a beta of 1.75. Imunon has a 12 month low of $0.46 and a 12 month high of $3.65. The stock’s fifty day moving average price is $0.87 and its 200-day moving average price is $0.87.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.07. Analysts forecast that Imunon will post -1.68 earnings per share for the current year.

Hedge Funds Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC grew its holdings in Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.